紫杉醇脂质体治疗进展期胃癌的疗效及安全性研究

目的 探讨紫杉醇（PTX）脂质体联合氟尿嘧啶衍生物（S-1）治疗进展期胃癌的疗效及不良反应。方法 选取2016年1月—2018年6月在苏州大学附属张家港医院和张家港市中医医院治疗的进展期胃癌患者97例，根据患者最终选取的治疗方案分为观察组（47例）和对照组（50例）。观察组给予PTX脂质体联合氟尿嘧啶衍生物（S-1）治疗，对照组给予PTX注射液联合S-1治疗，观察两组疗效、中位无进展生存时间和不良反应。结果 两组近期疗效比较，差异无统计学意义（P?>0.05），两组有效率分别为44.68%和46.00%；两组中位无进展生存时间分别为7个月（95% CI：6.57，7.43）和6个月（95% CI：5.67，6.33），比较差异无统计学意义（P?>0.05）；观察组骨髓抑制、脱发及关节肌肉疼痛较对照组轻（P?<0.05）；观察组和对照组恶心呕吐、肝功能受损及外周神经不良反应比较，差异无统计学意义（P?>0.05）。结论 PTX脂质体联合S-1治疗进展期胃癌有一定疗效，具有不良反应轻的优点。

Efficacy and safety of paclitaxel liposomes in the treatment of advanced gastric cancer

Objective To investigate the efficacy of paclitaxel (PTX) liposome combined with fluorouracil derivatives (S-1) in the treatment of advanced gastric cancer. Methods Totally 97 patients with advanced gastric cancer treated in Zhangjiagang Hospital Affiliated to Soochow University and Zhangjiagang Hospital of Traditional Chinese Medicine, from January 2016 to June 2018, were divided into observation group (n?=?47) and control group (n?=?50) according to the final treatment plan. The observation group was treated with PTX liposome combined with S-1, while the control group was treated with conventional PTX combined with S-1. The curative effect, median progression free survival time and adverse reactions of the two groups were observed. Results There was no significant difference in short-term efficacy between the observation group and the control group (P?>?0.05); the effective rates of the two groups were 44.68% and 46.00% respectively; the median progression-free survival time in the observation group and the control group were 7 months (95% CI: 6.57, 7.43) and 6 months (95% CI: 5.67, 6.33), and the difference was not statistically significant (P?>?0.05); The bone marrow suppression, alopecia and muscle joint pain in the observation group were lighter than those in the control group (P??0.05). Conclusion PTX liposome combined with S-1 is effective in the treatment of advanced gastric cancer, and has the advantage of mild side effects.